- Record: found
- Abstract: not found
- Article: not found
Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema
Richard Sinert ,
Phillip Levy ,
Jonathan A. Bernstein ,
Richard Body ,
Marco L.A. Sivilotti ,
Joseph Moellman ,
Jennifer Schranz ,
Jovanna Baptista ,
Alan Kimura ,
Wolfram Nothaft
September 2017
September 2017
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Upper airway angioedema is a rare, unpredictable, and at times life-threatening adverse
effect of angiotensin-converting enzyme inhibitors (ACE-Is) with no existing effective
pharmacologic treatment. Icatibant is a bradykinin B2 receptor antagonist that may
be beneficial in patients with ACE-I-induced angioedema.